P. Specenier

发表

A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Filip Lardon, J. Vermorken, F. Lardon, 2010, The oncologist.

The prognostic value of patient-reported Health-Related Quality of Life and Geriatric Assessment in predicting early death in 6769 older (≥ 70 years) patients with different cancer tumors.

C. Quinten, H. Wildiers, K. Milisen, 2020, Journal of geriatric oncology.

Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.

M. Benasso, O. Vanderveken, M. Peeters, 2016, The oncologist.

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor

P. Pauwels, M. Peeters, J. Vermorken, 2016, Medicinal research reviews.

Optimal treatment for recurrent/metastatic head and neck cancer.

J B Vermorken, J. Vermorken, P. Specenier, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma

J. Vermorken, P. Specenier, 2018, Expert review of anticancer therapy.

Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab

O. Vanderveken, J. Vermorken, E. Marck, 2016, European Archives of Oto-Rhino-Laryngology.

Targeted Therapies in Squamous Cell Carcinoma of the Head and Neck

P. Specenier, 2015 .

Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response

C. Boeckx, P. Pauwels, M. Peeters, 2014, BMC Research Notes.

Cetuximab in the treatment of squamous cell carcinoma of the head and neck

J. Vermorken, P. Specenier, 2011, Expert review of anticancer therapy.

Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status

P. Pauwels, M. Peeters, J. Vermorken, 2019, Cancers.

In vitro study of the Polo‐like kinase 1 inhibitor volasertib in non‐small‐cell lung cancer reveals a role for the tumor suppressor p53

P. Pauwels, M. Peeters, J. Vermorken, 2019, Molecular oncology.

Recurrent head and neck cancer: current treatment and future prospects

J. Vermorken, P. Specenier, 2008, Expert review of anticancer therapy.

A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms

J. V. van Meerbeeck, O. Vanderveken, B. D. De Winter, 2020, Frontiers in Oncology.

Pembrolizumab use for the treatment of advanced melanoma

P. Specenier, 2017, Expert opinion on biological therapy.

Ipilimumab in melanoma

P. Specenier, 2012, Expert review of anticancer therapy.

Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients

T. Ciuleanu, J. Latz, J. Vermorken, 2009, Cancer Chemotherapy and Pharmacology.

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

J. Vermorken, P. Specenier, 2012, ISRN oncology.

EGFR-directed therapies in squamous cell carcinoma of the head and neck

J. Vermorken, P. Specenier, 2012 .

Concurrent high-dose cisplatin-based chemoradiation (CCRT) is the preferred standard of care for patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) (1,2). The addition of cetuximab to irradiation (RT) improves locoregional control and prolongs progression-f

J. Vermorken, P. Specenier, 2016 .

Dual time point imaging in locally advanced head and neck cancer to assess residual nodal disease after chemoradiotherapy

A. Maes, O. Hoekstra, R. de Bree, 2022, EJNMMI Research.

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

A. Brandes, O. Chinot, W. Wick, 2016, Neuro-oncology.

Ipilimumab in melanoma

P. Specenier, 2012, Expert review of anticancer therapy.

Cetuximab: its unique place in head and neck cancer treatment

J. Vermorken, P. Specenier, 2013, Biologics : targets & therapy.

Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus

C. D. De Block, Katrien Clotman, I. Weets, 2018, The Journal of clinical endocrinology and metabolism.

Matrix Metalloproteinases in Head and Neck Cancer

Anja Brouwer, P. Specenier, A. Brouwer, 2015 .

Immunotherapy in squamous cell carcinoma of the head and neck ( HNSCC )

P. Specenier, 2022 .

EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

D. Lacombe, J. Bogaerts, J. Langendijk, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Current concepts for the management of head and neck cancer: chemotherapy.

J. Vermorken, P. Specenier, 2009, Oral oncology.

TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial

É. Remenár, A. Awada, J. Buter, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Functional status in older patients with cancer and a frailty risk profile: A multicenter observational study.

H. Wildiers, K. Milisen, G. Jerusalem, 2022, Journal of geriatric oncology.

Cost-effectiveness of nivolumab in advanced melanoma: a drug review

P. Specenier, 2020, Expert review of pharmacoeconomics & outcomes research.

Nivolumab in squamous cell carcinoma of the head and neck

P. Specenier, 2018, Expert review of anticancer therapy.

Efficacy of nab-paclitaxel in treating metastatic melanoma

P. Specenier, 2019, Expert opinion on pharmacotherapy.

Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy

J. V. van Meerbeeck, O. Vanderveken, M. Peeters, 2021, PloS one.

Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients

J. Weyler, J. Vermorken, K. Aelbrecht, 2011, Cancer Chemotherapy and Pharmacology.

A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck

J. Weyler, J. Vermorken, M. Huizing, 2009, BMC Cancer.

Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.

J. Weyler, M. Huizing, D. Schrijvers, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

New medical treatments in thyroid cancer

L. Decoster, S. Henry, P. Clement, 2014 .

Induction chemotherapy in squamous cell carcinoma of the head and neck: saved by the bell?

P. Specenier, 2015, Oral oncology.

Premedication strategy for paclitaxel, still an unsolved question after 30 years

P. Specenier, C. Verschueren, E. Dewaele, 2017 .

Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy.

J. Vermorken, C. Koppen, P. Specenier, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-1 inhibitor induced type 1 diabetes mellitus Programmed cell death-1 ( PD-1 ) inhibitor induced type 1 diabetes mellitus : mini-review

Katrien Clotman, I. Weets, P. Specenier, 2022 .

Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium

H. Wildiers, K. Milisen, G. Jerusalem, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.

É. Remenár, A. Awada, J. Buter, 2016 .

Incidence of falls and fall-related injuries and their predictive factors in frail older persons with cancer: a multicenter study

H. Wildiers, K. Milisen, G. Jerusalem, 2022, BMC Geriatrics.

Tumors of the skin, the CNS and the head and neck

P. Specenier, 2013 .

Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins.

C. Boeckx, P. Pauwels, R. Limame, 2014, Cancer letters.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

The role of taxanes and targeted therapies in locally advanced head and neck cancer

J. Vermorken, P. Specenier, 2007, Current opinion in oncology.

Targeted therapies in head and neck cancer

J. Vermorken, P. Specenier, 2007, Targeted Oncology.

Targeting the ErbB family in head and neck cancer

J. Vermorken, P. Specenier, 2007 .

A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck

J. Machiels, T. Gauler, S. Braun, 2015, Cancer Chemotherapy and Pharmacology.

Advances in the systemic treatment of head and neck cancers

J. Vermorken, P. Specenier, 2010, Current opinion in oncology.

Afatinib in squamous cell carcinoma of the head and neck

J. Vermorken, P. Specenier, 2016, Expert opinion on pharmacotherapy.

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

Sung-Bae Kim, K. Harrington, M. Ahn, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.

J. Machiels, I. Tinhofer, J. Canon, 2021, European journal of cancer.

Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.

C. Boeckx, M. Peeters, J. Vermorken, 2013, The oncologist.

Bevacizumab in glioblastoma multiforme

P. Specenier, 2012, Expert review of anticancer therapy.

Bevacizumab in glioblastoma

P. Specenier, 2012 .

Expression Analysis on Archival Material: Comparison of 5 Commercially Available RNA Isolation Kits for FFPE Material

C. Boeckx, P. Pauwels, M. Peeters, 2011, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Atypical Carcinoid Tumor of the Larynx: A Challenging Diagnostic Case

M. Lammens, P. Specenier, L. Carp, 2016 .

Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer

C. Rolfo, M. Peeters, K. Papadimitriou, 2015, Current Treatment Options in Oncology.

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

A. Brandes, A. von Deimling, O. Chinot, 2017, International journal of molecular sciences.

Ipilimumab in melanoma

P. Specenier, 2012, Expert review of anticancer therapy.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

A. Jimeno, J. Machiels, T. Seiwert, 2016, Cancer.

Evolution of self‐perceived swallowing function, tongue strength and swallow‐related quality of life during radiotherapy in head and neck cancer patients

L. Van den Steen, C. Lazarus, Gwen Van Nuffelen, 2019, Head & neck.

Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.

D. de Ruysscher, D. Ruysscher, J. Vansteenkiste, 1998, Lung Cancer.

Antineoplastic therapy-induced pulmonary toxicity

M. Peeters, P. Germonpré, P. Specenier, 2013, Expert review of anticancer therapy.

An overview of binimetinib for the treatment of melanoma

P. Specenier, 2020, Expert opinion on pharmacotherapy.

Nivolumab in melanoma

P. Specenier, 2016, Expert review of anticancer therapy.

Induction chemotherapy in head and neck cancer: are we too ambitious?

P. Specenier, 2014, Future oncology.

Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery

C. Quinten, H. Wildiers, K. Milisen, 2018, Quality of Life Research.

Neoadjuvant chemotherapy in head and neck cancer: should it be revisited?

J. Vermorken, P. Specenier, 2007, Cancer letters.

A phase I study of volasertib combined with afatinib, in advanced solid tumors

J. Machiels, N. Strelkowa, M. Peeters, 2015, Cancer Chemotherapy and Pharmacology.

Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines: focus on the contribution of the AP-1 transcription factor.

C. Boeckx, R. Limame, M. Peeters, 2015, American journal of cancer research.

Patient outcome in the Belgian medical need program on bevacizumab for recurrent glioblastoma

B. Neyns, B. Filleul, V. Verschaeve, 2015, Journal of Neurology.

Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study

J. Van den Brande, J. Vermorken, M. Huizing, 2010, Anti-cancer drugs.

Study protocol for a randomized controlled trial: prophylactic swallowing exercises in head-and-neck cancer patients treated with (chemo)radiotherapy (PRESTO trial)

L. Van den Steen, L. van der Molen, Gwen Van Nuffelen, 2020, Trials.

Helical tomotherapy in head and neck cancer: a European single-center experience.

V. Grégoire, O. Vanderveken, J. Vermorken, 2015, The oncologist.

Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors

P. Specenier, 2021, Current opinion in otolaryngology & head and neck surgery.

Feasibility of tongue strength measurements during (chemo)radiotherapy in head and neck cancer patients

L. Van den Steen, C. Lazarus, Gwen Van Nuffelen, 2017, Supportive Care in Cancer.

Study protocol for a randomized controlled trial: tongue strengthening exercises in head and neck cancer patients, does exercise load matter?

L. Van den Steen, Gwen Van Nuffelen, M. De Bodt, 2015, Trials.

Quality of life in oropharyngeal cancer: a structured review of the literature

Karina Tukanova, P. Specenier, Evelyne Roets, 2018, Supportive Care in Cancer.

Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.

J. Van den Brande, J. Vermorken, M. Huizing, 2009, Anticancer research.

A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators

H. Wildiers, K. Milisen, G. Jerusalem, 2015, The journal of nutrition, health & aging.

Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors.

H. Wildiers, K. Milisen, G. Jerusalem, 2020, Journal of Geriatric Oncology.

C. Quinten, H. Wildiers, K. Milisen, 2019, Journal of geriatric oncology.

A Belgian Survey on Geriatric Assessment in Oncology Focusing on Large-Scale Implementation and Related Barriers and Facilitators.

H. Wildiers, K. Milisen, G. Jerusalem, 2016, The Journal of Nutrition, Health & Aging.

Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study

A. Maes, O. Hoekstra, R. de Bree, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Safety interim data from a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression.

A. Brandes, O. Chinot, W. Wick, 2013 .

Long-term recurrence-free survival after hepatic resection for metachronous gastric cancer liver metastases

P. Specenier, B. Peeters, Jeroen Kerstens, 2016 .

CONCERT-1, an additional piece in the puzzle of (bio)-(chemo)-radiation.

J. Vermorken, P. Specenier, 2016, Annals of translational medicine.

Metastatic renal cell carcinoma : don't dismiss the surgeon

P. Specenier, Elisa Cassiers, 2015 .

Locoregionally advanced squamous cell carcinoma of the head and neck : chemoradiation or bioradiation

J. Vermorken, P. Specenier, 2016 .

A nationwide implementation of a multidisciplinary geriatric assessment and intervention program in belgian older patients with cancer

H. Wildiers, K. Milisen, G. Jerusalem, 2015 .

Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

J. Van den Brande, P. Vroman, J. Vermorken, 2011, American journal of clinical oncology.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor

P. Pauwels, M. Peeters, J. Vermorken, 2016, Medicinal research reviews.

ACUTE HEMIPLEGIA CAUSED BY A RETROGRADE CEREBRAL VENOUS AIR EMBOLISM AFTER CENTRAL VENOUS CATHETER REMOVAL: AN ILLUSTRATIVE CASE.

P. Jorens, J. Vermorken, P. Specenier, 2010, Acta clinica Belgica.

Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study.

J. Machiels, T. Gauler, A. Dietz, 2013 .

Cetuximab in the treatment of squamous cell carcinoma of the head and neck

J. Vermorken, P. Specenier, 2011, Expert review of anticancer therapy.

Abstracts presented at the 22nd Annual Congress of the Belgian Society of Internal Medicine, 15–16 December 2017, Dolce La Hulpe, La Hulpe, Belgium

J. Souberbielle, O. Descamps, E. Cavalier, 2017, Acta clinica Belgica.

Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

Sung-Bae Kim, K. Harrington, M. Ahn, 2019, Clinical Trials.

Severe oral mucositis (SOM) mitigation by genetically modified lactococcus lactis bacteria (LLB) producing human trefoil factor 1 (hTFF1; AG013) in patients being treated with concomitant chemoradiation (CRT) for oral and oropharyngeal cancers (OCOPC)

Yuhchyau Chen, S. Sonis, S. Thatcher, 2019, Annals of Oncology.